middle.news
Patrys takes RLS-2202 into human trials despite funding warning
5:32pm on Monday 28th of September, 2026 AEST
•
Biotechnology and Pharmaceuticals
Read Story
Patrys takes RLS-2202 into human trials despite funding warning
5:32pm on Monday 28th of September, 2026 AEST
Key Points
First participants dosed in RLS-2202 Phase 1A trial after year-end
$3.42 million FY2026 net loss and $2.17 million operating cash outflow
Material going concern uncertainty linked to future funding requirements
$6.636 million RLS-2202 intangible recognised after Reliis acquisition
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Patrys (ASX:PAB)
OPEN ARTICLE